VBI-2905 / VBI Vaccines - LARVOL DELTA

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a (clinicaltrials.gov) - P1 | N=114 | Completed | Sponsor: VBI Vaccines Inc. | Phase classification: P1a/1b ➔ P1

Phase classification • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a (clinicaltrials.gov) - P1a/1b | N=114 | Completed | Sponsor: VBI Vaccines Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a (clinicaltrials.gov) - P1a/1b | N=114 | Active, not recruiting | Sponsor: VBI Vaccines Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a (clinicaltrials.gov) - P1a/1b; N=141; Recruiting; Sponsor: VBI Vaccines Inc.; Active, not recruiting ➔ Recruiting; Phase classification: P1/2 ➔ P1a/1b; N=780 ➔ 141; Trial completion date: Jun 2022 ➔ Nov 2022; Trial primary completion date: Jun 2022 ➔ Nov 2022

Clinical • Enrollment change • Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases